

Sofia Berglund

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1110780/publications.pdf>

Version: 2024-02-01

22
papers

816
citations

623574

14
h-index

839398

18
g-index

22
all docs

22
docs citations

22
times ranked

1593
citing authors

#	ARTICLE	IF	CITATIONS
1	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. <i>Blood</i> , 2018, 131, 247-262.	0.6	164
2	Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1688-1697.	2.0	131
3	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. <i>JCI Insight</i> , 2018, 3, .	2.3	123
4	Rapid Salvage Treatment With Virus-Specific T Cells for Therapy-Resistant Disease. <i>Clinical Infectious Diseases</i> , 2012, 55, 1064-1073.	2.9	116
5	Advances in umbilical cord blood cell therapy: the present and the future. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 691-699.	1.4	50
6	Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 666-677.	2.0	45
7	Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 811-827.	1.4	27
8	Mesenchymal Stem Cells Inhibit Thymic Reconstitution After Allogeneic Cord Blood Transplantation. <i>Stem Cells and Development</i> , 2012, 21, 1409-1417.	1.1	26
9	Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients. <i>Clinical Epigenetics</i> , 2018, 10, 102.	1.8	24
10	Expansion of Gammadelta T Cells from Cord Blood: A Therapeutical Possibility. <i>Stem Cells International</i> , 2018, 2018, 1-15.	1.2	22
11	Factors With an Impact on Chimerism Development and Long-Term Survival After Umbilical Cord Blood Transplantation. <i>Transplantation</i> , 2012, 94, 1066-1074.	0.5	20
12	Characterization of long-term mixed donorâ€“donor chimerism after double cord blood transplantation. <i>Clinical and Experimental Immunology</i> , 2010, 162, 146-155.	1.1	17
13	Stable mixed donorâ€“donor chimerism after double cord blood transplantation. <i>International Journal of Hematology</i> , 2009, 90, 526-531.	0.7	15
14	Expanded umbilical cord blood T cells used as donor lymphocyte infusions after umbilical cord blood transplantation. <i>Cytotherapy</i> , 2014, 16, 1528-1536.	0.3	15
15	Cord Blood T Cells Cultured With IL-7 in Addition to IL-2 Exhibit a Higher Degree of Polyfunctionality and Superior Proliferation Potential. <i>Journal of Immunotherapy</i> , 2013, 36, 432-441.	1.2	12
16	Granulocyte transfusions could benefit patients with severe oral mucositis after allogeneic hematopoietic stem cell transplantation. <i>Vox Sanguinis</i> , 2019, 114, 769-777.	0.7	4
17	Expansion of T-cells from the cord blood graft as a predictive tool for complications and outcome of cord blood transplantation. <i>Clinical Immunology</i> , 2012, 143, 134-144.	1.4	3
18	Chimerism and use of mesenchymal stem cells in umbilical cord blood transplantation. <i>Chimerism</i> , 2013, 4, 34-35.	0.7	1

#	ARTICLE	IF	CITATIONS
19	Umbilical cord blood T cells cultured with IL-7 in addition to IL-2 exhibit a higher degree of polyfunctionality and superior proliferation potential. <i>Frontiers in Immunology</i> , 0, 4, .	2.2	1
20	Stable Mixed Donor-Donor Chimerism after Double Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 114.	2.0	0
21	In Vitro Expanded Umbilical Cord Blood T Cells Used for Donor Lymphocyte Infusions after Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S147.	2.0	0
22	Natural Killer Cell Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Elimination of Donor-Derived Mature Alloreactive NK Cells, but Favorable Conditions for Adoptive Immunotherapy. <i>Blood</i> , 2016, 128, 4567-4567.	0.6	0